Development and Validation of Midostaurin Assay by RP-HPLC Method
DOI:
https://doi.org/10.37285/ijpsn.2018.11.6.4Abstract
Midostaurin is a multi-targeted protein kinase inhibitor that has been used for the treatment of acute myeloid leukemia. Here, a rapid and precise reverse phase high-performance liquid chromatographic method has been developed for the validation of midostaurin, in its API form as well as in capsule dosage form. Chromatography was carried out on a X-Bridge C18 (4.6 x 250 mm, 5 µm) column using a mixture of methanol: water (75:25% v/v) as the mobile phase at a flow rate of 1.0 mL/min, the detection was carried out at 243nm and the retention time of the midostaurin was found to be 3.155. The method produce linear responses in the concentration range of 10-50 µg/mL of midostaurin. The method precision for the determination of assay was below 2.0 % RSD. The LOD and LOQ values obtained were 1.2 µg/mL and 3.8 µg/mL respectively. There were no significant changes observed upon changing chromatographic conditions indicating the method to be robust. Therefore this validated method can be useful in the quality control of bulk and pharmaceutical formulations of midostaurin.
Downloads
Metrics
Keywords:
Midostaurin, HPLC, Validation, Retention time, Quality control
Downloads
Published
How to Cite
Issue
Section
References
Bourget P, Chandesris MO, Amin A, Vidal F, Merlette C, Hirsh I, Carvalhosa A, Mogenet A, Broissand C, Giraud B and Frenzel L (2012). Development and Validation of a Sensitive Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Assay for the Simultaneous Quantification of Midostaurin (PKC412) and Its Two Major Metabolites: A Suitable Tool for the Monitoring of the Drug in Patients Suffering From Advanced Systemic Mastocytosis. Blood 120:4913.
Fischer T, Stone RM, DeAngelo DJ, Galinsky I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ and Klimek VM (2010). Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 28(28):4339.
He H, Tran P, Gu H, Tedesco V, Zhang J, Lin W, Gatlik E, Klein K and Heimbach T (2017). Midostaurin, a novel protein kinase inhibitor for the treatment of acute myelogenous leukemia: insights from human absorption, metabolism and excretion studies of a BDDCS II drug. Drug Metab Dispo 45(5):540-555.
ICH (2005). Guideline IH. Validation of analytical procedures: text and methodology Q2 (R1). International Conference on Harmonization, Geneva, Switzerland 2005: 11-12.
Kim ES. Midostaurin: First Global Approval. Drugs 77:1251–1259.
Meyer T, Regenass U, Fabbro D, Alteri E, Röusel J, Möller M, Caravatti G and Matter A (1989). A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity. Int J Cancer 43(5):851-6.
Tvedt TH, Nepstad I, and Bruserud Ø (2017). Antileukemic effects of midostaurin in acute myeloid leukemia–the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Exp. Opin. Invest. Drugs 26(3):343-55.
Valent P, Akin C, Hartmann K, George TI, Sotlar K, Peter B, Gleixner KV, Blatt K, Sperr WR, Manley PW and Hermine O (2017). Midostaurin: a magic bullet that blocks mast cell expansion and activation. Ann Oncol 28(10):2367-76.
Weisberg E, Sattler M, Manley PW, and Griffin JD (2018). Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy. OncoTargets Ther 11:175-182.
